Full-Time
Clinical Project Manager/Sr. Project Manager
Glaukos
1,001-5,000 employees
Medical devices for glaucoma treatment
Compensation Overview
$109.1k - $141.8k/yr
Aliso Viejo, CA, USA
In Person
 Business & Strategy (1) |
|---|
Get referred to Glaukos
See people who can refer or advise you
- Bachelor’s Degree Required
- 5 plus years of Clinical project management experience in medical device or pharmaceutical industries
- Knowledge of pharmaceutical and/or medical device development processes and deliverables at each stage of the pipeline, from early development to commercialization
- Experience in project management tools including Microsoft Project, Excel, SharePoint and PowerPoint; Advanced knowledge of analytical tools preferred
- Oversee integrated project timelines and establish and maintain clinical study metrics to aid strategy development and decision making
- Support clinical teams with the development of project plans, timelines, and resource allocation for clinical trials and related activities
- Facilitate cross functional strategic discussions to ensure all elements of applicable project development are planned and executed
- Collaborate with cross-functional teams to ensure alignment with organizational goals
- Create and maintain clinical studies metrics that will aid decision making and identify bottlenecks
- Identify and manage risks, assisting in the development of proactive mitigation strategies
- Communicate transparently and concisely to relevant stakeholders regarding clinical study status, plans, risks and strategy
- Exercise excellent judgment in determining appropriate project communications to internal and external stakeholders
- Proactively identify critical path constraints and work with R&D management to identify solutions
- Promote implementation and cross functional adoption of “fit for purpose” PMO tools, including MS Project, consistent use of SharePoint, and reporting and analytics tools
- Promote implementation and cross functional adoption of project management best practices and assist with training and development supporting the implementation of the organization’s PMO
- Contribute to the development and refinement of project management processes, tools, and best practices within the clinical development and operations teams
- Any clinical research or clinical operations experience would be preferable but not required
- Advanced knowledge of analytical tools is preferred
- Experience with Microsoft Project, Excel, SharePoint and PowerPoint as part of project management tools is preferred
Glaukos focuses on ophthalmology by developing and commercializing medical devices and therapies for glaucoma, corneal disorders, and retinal diseases. Its products mainly target surgeons who treat eye conditions, with a core technology in micro invasive glaucoma surgery (MIGS). The company’s MIGS devices, such as the Trabecular Micro Bypass Stent and next-generation iStent, are implanted in the eye to improve outflow of eye fluid and lower intraocular pressure, offering a less invasive option compared with traditional surgeries. Glaukos differentiates itself by pioneering MIGS and bringing the first US-approved MIGS device to market in 2012, continuing to expand its portfolio through research, development, and strategic acquisitions. The company aims to improve patient care by providing safer, effective, and longer-lasting treatment options for glaucoma and related eye diseases, addressing unmet needs in ophthalmology.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Aliso Viejo, California
Founded
1998
Get referred to Glaukos
See people who can refer or advise you
Simplify's Take
What believers are saying
- Glaukos reported record Q1 2026 glaucoma net sales of $129.3 million, up 47% year-over-year[2].
- Permanent J-code J2789 effective July 1, 2026 streamlines reimbursement and expands payer coverage for Epioxa[1].
- Orsini Specialty Pharmacy serves as single-source partner to accelerate rare disease patient access for Epioxa[2].
What critics are saying
- Major insurers like Aetna exclude Epioxa coverage due to 'experimental' status, risking near-zero adoption[2].
- $78,500 wholesale cost is 3–5× higher than traditional CXL, triggering severe payer resistance and denials[2].
- Discontinuing Photrexa in 2026 creates a cash gap amid $187.7M operating losses without guaranteed Epioxa uptake[2].
What makes Glaukos unique
- Glaukos pioneered MIGS and launched the first US-approved MIGS device in 2012[1].
- Epioxa is the only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus[2].
- Epioxa uses oxygen-enriched, UV-activated topical formulation without epithelium removal[2].
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%Glaukos receives permanent J-code for Epioxa(TM). New J-code for Epioxa(TM), J2789, set to become effective July 1, 2026. April 17, 2026 Glaukos Corporation announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa(TM) HD/Epioxa(TM)("Epioxa") for the treatment of keratoconus. ABOUT the code. The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the reporting and payment of Epioxa by U.S. payers over time. "The assignment of a product-specific J-code for Epioxa represents an important milestone, supporting our market access initiatives to increase access and expand coverage for patients suffering from keratoconus," said Thomas Burns, Glaukos chairman and chief executive officer. "Once effective, this new J-code is expected to enable more streamlined and consistent coverage and payment for Epioxa over time, strengthening the foundation for our commercial launch and enabling broader patient access." J-codes are reported by U.S. health care providers and used by U.S. government and commercial payers to streamline the billing and reimbursement process for pharmaceuticals, such as Epioxa, administered by a health care professional. Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to eliminate the pain associated with removal of the epithelium, streamline the procedure and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers and the health care system. ABOUT EPIOXA HD/EPIOXA Indication: EPIOXA(TM) HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA(TM)(riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n(TM) System and the Boost Goggles(R). Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator's Manual and Boost Goggles User Guide for device instructions. Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens. Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis. Adverse Reactions: The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.